- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00002093
A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
June 23, 2005 updated by: Nexstar Pharmaceuticals
To compare the toxicity profiles (severity and time to onset from initiation of therapy) between daunorubicin (liposomal) and combination chemotherapy with doxorubicin/bleomycin/vincristine (ABV), with both regimens administered in combination with antiretroviral therapy.
To compare the duration of responses, response rates, and times to response.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- Univ of Arizona / Arizona Cancer Ctr
-
-
California
-
Los Angeles, California, United States, 90033
- Kenneth Norris Jr Cancer Hosp
-
Palm Springs, California, United States, 92262
- Desert Hosp Comprehensive Cancer Ctr
-
San Francisco, California, United States, 94114
- Davies Med Ctr
-
San Francisco, California, United States, 94109
- Saint Francis Mem Hosp
-
-
Colorado
-
Denver, Colorado, United States, 802044507
- Denver Gen Hosp
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- George Washington Univ Med Ctr
-
-
Florida
-
Miami, Florida, United States, 33136
- Univ of Miami Dept of Medicine
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Univ Med School
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- New England Deaconess Hosp
-
-
New York
-
New York, New York, United States, 10016
- New York Univ Med Ctr
-
-
Oregon
-
Portland, Oregon, United States, 97227
- Kaiser Permanente Med Ctr
-
-
Texas
-
Houston, Texas, United States, 77004
- Dr Edward Stool
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
Patients must have:
- HIV infection.
- Advanced Kaposi's sarcoma.
Prior Medication:
Allowed:
- Prior intralesional vinblastine.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
- Acute intercurrent infection other than genital herpes.
- Uncompensated cardiovascular, hepatic, renal, or pulmonary disease unrelated to Kaposi's sarcoma.
- Symptomatic peripheral neuropathy.
- Any condition that compromises ability to give informed consent or complete the study.
Concurrent Medication:
Excluded:
- Concurrent ganciclovir.
Patients with the following prior conditions are excluded:
- Symptomatic AIDS-defining opportunistic infection within 2 weeks of entry.
- History of malignancy other than Kaposi's sarcoma, basal cell carcinoma, or carcinoma in situ of the cervix.
Prior Medication:
Excluded:
- Prior systemic chemotherapy.
- Intralesional therapies within 7 days prior to study entry.
- Growth factors (G-CSF or GM-CSF), immune modifiers, or investigational agents within 14 days prior to study entry.
- Interferon preparations (alpha or beta) within 28 days prior to study entry.
Prior Treatment:
Excluded within 7 days prior to study entry:
- Radiation.
- Local therapies (e.g., cryotherapy).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996 Aug;14(8):2353-64. doi: 10.1200/JCO.1996.14.8.2353.
- Savage GE, Gable C, Motte K, Dixon C, Becker R. A pharmacoeconomic analysis of Kaposi's sarcoma patients based on a clinical trial of ABV vs. DaunoXome. Int Conf AIDS. 1996 Jul 7-12;11(Program Supplement):32 (abstract no LBB6048)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
November 2, 1999
First Submitted That Met QC Criteria
August 30, 2001
First Posted (Estimate)
August 31, 2001
Study Record Updates
Last Update Posted (Estimate)
June 24, 2005
Last Update Submitted That Met QC Criteria
June 23, 2005
Last Verified
March 1, 1996
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- DNA Virus Infections
- Herpesviridae Infections
- Neoplasms, Vascular Tissue
- Sarcoma
- Sarcoma, Kaposi
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Doxorubicin
- Liposomal doxorubicin
- Vincristine
- Daunorubicin
- Bleomycin
Other Study ID Numbers
- 121A
- 103-09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Bleomycin sulfate
-
Jinnah Postgraduate Medical CentreCompletedCutaneous WartsPakistan
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)UnknownMelanoma (Skin)United States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed
-
Ichor Medical Systems IncorporatedNational Cancer Institute (NCI)Withdrawn
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of California, Los Angeles; University... and other collaboratorsCompletedHuman Immunodeficiency Virus 1 Positive | AIDS-Related Kaposi SarcomaTanzania
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI); North Central Cancer Treatment GroupCompleted
-
National Institute of Allergy and Infectious Diseases...Amgen; Sequus PharmaceuticalsCompletedHIV Infections | Sarcoma, KaposiUnited States
-
Sequus PharmaceuticalsCompletedHIV Infections | Sarcoma, KaposiUnited States
-
Medical Research CouncilCompletedTesticular Germ Cell Tumor | Teratoma | Extragonadal Germ Cell TumorUnited Kingdom
-
Sequus PharmaceuticalsUnknownHIV Infections | Sarcoma, KaposiUnited States